Abstract:Background: Currently, no satisfactory biomarkers are available to screen for lung cancer. Surface-Enhanced Laser Desorption/ionization Time-of- Flight Mass Spectrometry ProteinChip system (SELDI-TOF-MS) is one of the currently used techniques to identify biomarkers for cancers. The aim of this study is to explore the application of serum SELDI proteomic patterns to distinguish lung cancer patients from healthy individuals.Methods: A total of 208 serum samples, including 158 lung cancer patients and 50 healthy individuals, were randomly divided into a training set (including 11 sera from patients with stages I/II lung cancer, 63 from patients with stages III/IV lung cancer and 20 from healthy controls) and a blinded test set (including 43 sera from patients with stages I/II lung cancer, 41 from patients with stages III/IV lung cancer and 30 from healthy controls). All samples were analyzed by SELDI technology. The spectra were generated on weak cation exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively. We additionally determined Cyfra21-1 and NSE in the 208 serum samples included in this study using an electrochemiluminescent immunoassay.Results: Five protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a biomarker pattern in the training set. When the SELDI marker pattern was tested with the blinded test set, it yielded a sensitivity of 86.9%, a specificity of 80.0% and a positive predictive value of 92.4%. The sensitivities provided by Cyfra21-1 and NSE used individually or in combination were significantly lower than that of the SELDI marker pattern (P < 0.005 or 0.05, respectively). Based on the results of the test set, we found that the SELDI marker pattern showed a sensitivity of 91.4% in the detection of non-small cell lung cancers (NSCLC), which was significantly higher than that in the detection of small cell lung cancers (P < 0.05); The pattern also had a sensitivity of 79.1% in the detection of lung cancers in stages I/II.Conclusion: These results suggest that serum SELDI protein profiling can distinguish lung cancer patients, especially NSCLC patients, from normal subjects with relatively high sensitivity and specificity, and the SELDI- TOF- MS is a potential tool for the screening of lung cancer.

Diagnostic potential of protein serum biomarkers for distinguishing small and non-small cell lung cancer in patients with suspicious lung lesions

Meta-Analysis of Serum Gastrin-Releasing Peptide Precursor As a Biomarker for Diagnosis of Small Cell Lung Cancer

Biomarker Discovery and Identification from Non-Small Cell Lung Cancer Sera.

A Preliminary Analysis of Non-Small Cell Lung Cancer Biomarkers in Serum.

Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer.

New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1

New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?

Prognostic Value of Serum Tumor Markers in Patients with Lung Cancer

The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer

Role of a serum‐based biomarker panel in the early diagnosis of lung cancer for a cohort of high‐risk patients

Biomarkers in the Lung Cancer Diagnosis: a Clinical Perspective.

Application of Serum Seldi Proteomic Patterns in Diagnosis of Lung Cancer

Diagnostic Value of Cytokeratin-19 Fragments, Neuron Specific Enolase and Pro-Gastrin Releasing Peptide in Serum for Primary Lung Cancer

Alterations in Serum Protein Glycopatterns Related to Small Cell Lung Cancer, Adenocarcinoma and Squamous Carcinoma of the Lung.

Tumor-derived exosomal miR-155-5p and miR-658 in serum as diagnostic biomarkers for early-stage non-small cell lung cancer

[Serum Proteomic Patterns May Assist the Diagnosis of Solitary Pulmonary Nodules].

Diagnostic significance of S100A2 and S100A6 levels in sera of patients with non-small cell lung cancer

Comparative Analysis of Serum Proteomes for Discovery of Biomarkers for Human Lung Squamous Carcinoma

Multiplexed Serum Biomarkers for the Detection of Lung Cancer.

Serum Amyloid A Protein: a Potential Biomarker Correlated with Clinical Stage of Lung Cancer.

[Diagnostic Value of Serum Tumor Markers in Differentiating Malignant from Benign Solitary Pulmonary Nodules].